
25 Feb 2021
Hikma Pharmaceuticals (Hold) - FY20 results in line, but FY21 guidance implies downgrades
This content is only available within our institutional offering.

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Hikma Pharmaceuticals (Hold) - FY20 results in line, but FY21 guidance implies downgrades
Hikma Pharmaceuticals Plc (HIK:LON) | 1,836 0 0.0% | Mkt Cap: 4,074m
- Published:
25 Feb 2021 -
Author:
Miles Dixon | Amy Walker | Anchal Verma -
Pages:
6 -